SCIENTIFIC PROGRAM DAY TWO
7:15 am Check In, Morning Coffee & Refreshments
7:15 am Breakfast Briefing: Sartoflow® Expert SU for Streamlined ADC Manufacturing in Pilot Scale
8:10 am Chair’s Opening Remarks
Showcasing Cutting-Edge Successes of ADC Combinations Reshaping Frontline Treatments in Oncology
8:15 am Breaking Down the Success from the Padcev-Keytruda Combination & Applying Learnings to Future ADC-Immunotherapy Combinations
Synopsis
- Highlighting safety and clinical outcome readouts from the Phase III combination trial in bladder cancer
- Breaking down strategy, rationale, partnering, and lessons learned advancing through preclinical and clinical strategies
- Evaluating the future of ADC-immunotherapy and other novel combinations with ADCs to redefine patient experience and standard of care
8:45 am Versatile & Robust Chemical Site-Specific Conjugation Platform: AJICAP® Technology
Synopsis
- AJICAP® Conjugation: Examining how site-specific technologies are being employed in many of the next-generation ADCs due to the enhancement of clinically relevant biological properties observed in various preclinical studies
- AJICAP® Linker: Demonstrating a novel hydrophilic linker technology that enables the versatile synthesis of homogenous DAR = 1, 2, 4, 8, and higher
- Showcasing Bispecific and Trispecific antibodies produced by fully-chemical conjugation technology
9:15 am Trodelvy-Immunotherapy Combinations In Solid Tumors: Rationale & Emerging Data
Synopsis
- Recapping and contextualizing recent data from Phase II EVOKE-02 trial of Troveldy-Keytruda combinations in lung cancer
- Evaluating rationale and design of Trodelvy-immunotherapy combinations in other solid tumors
- Breaking down the potential – what are the route forward and potential of novel ADC-immunotherapy combinations?
9:45 am A Reliable & Flexible Technology for the Rapid Conjugation of Antibodies & Other Biologics
Synopsis
- Describing how Singzyme provides a one-stop solution for antibodies and nanobodies engineering and conjugation
- Exploring how Singzyme’s technology accelerates the development of cancer immunotherapy, allowing faster production of antibody-drug-conjugates with minimal footprint on the final product and the possibility to attach two payloads with a defined DAR
- Exploring Singzyme’s technology which allows imaging for disease diagnosis: production of radiopharmaceuticals for PET scan imaging (Nanobodies or mAbs) with minimal radioactive waste thanks to the highest conjugation efficiency on the market
10:15 am Accelerated Pathway from Antibody to ADC: Chemistry Matters
Synopsis
- The pathway from antibody to ADC is complex, resource intensive, and time-consuming
- There are numerous platform-based solutions including various payload classes, differing linker chemistries, and conjugation technologies to evaluate
- This talk will demonstrate how having high-quality material, expertize and the right technology can accelerate your ADC programs
10:30 am Morning Break & Technology Slam
Synopsis
As you enjoy your morning refreshments, you will also have the chance to be face-to-face with the field’s most innovative and exciting technology providers. Join our dedicated technology slam to identify your next technology provider and progress your antibody-drug conjugate pipeline smoothly and efficiently. If you didn’t get a chance to visit all the posters from day one – they will still be up during this break too!
Discovery Chemistry
Download the Full Event Guide for full details
Diving Into Innovations in ADC Linker-Payload Chemistry for Next Generation ADC Development
11.30 am Harnessing AbClick Pro for AT-211 Yields a CLDN 18.2 Targeting ADC with Superior Therapeutic Index Among Comparable ADCs
Sang Jeon Chung, Chief Scientific Officer, AbTis
12.00 pm HDP-201, a Multimeric Linker-Exatecan-based ADC as Novel Therapeutic Modality for Treatment of Solid Tumors
Andreas Pahl, Chief Executive Officer, Heidelberg Pharma
12.30 pm Showcasing NMS’s Portfolio of Cytotoxins & Targeted Payloads to Drive ADC Innovation
Barbara Valsasina, ADC Portfolio Head, Nerviano Medical Sciences
12.45 pm Click Chemistry Enabled Pre-targeting as a Solution to Target Independent ADC Toxicities
Jose Mejia Oneto, Founder & Chief Executive Officer, Shasqi
1.00 pm Lunch and Networking By Cytiva
Maximizing ADC Discovery Characterization to Bring Clinical Benefit
2.00 pm Showcasing the T-Moiety Linker Platform to Expand Payloads Used in ADCs
Xiaona Jing, Senior Vice President, Global Product Development & Partnering, Multitude Therapeutics
2.30 pm Breaking Down the Foresight During Discovery to Maximize Impact in the Clinic
Gerhard Frey, Vice President, Technology Development, BioAtla
3.00 pm Optimizing Homogenous High DAR ADCs: Discovery of Hydrophilic Beta-Glucuronidase Cleavable Topo1 & Microtubulin Inhibitor Linker Payloads for Enhanced Efficacy & Safety
Krishna Bajjuri, Senior Director, Chemistry, Sutro Biopharma
3:30 pm Afternoon Break & Networking
BCMA Breakdown: Exploring Case Studies of ADC Development for Targets Without an Approved Therapy
4:00 pm ATACs: A New Payload Provides New Options for Cancer Therapy
Synopsis
- Discussing a payload with a new mode of action providing new options to fight cancer
- Understanding how the ATAC platform optimized the ADC technology for that unique payload
- Clinical update on HDP-101 targeting BCMA; the first ATAC which is now in dose escalation in myeloma patients
4:30 pm Tubulis – Pushing the Boundaries of ADCs
Synopsis
- Advancing multiple ADC programs into the clinic, based on its novel Tubutecan linker-payload system to enable optimized, sustained on-tumor Topo-1 payload delivery
- In discovery, developing a novel linker component (Alco5) to broadly unlock novel ADC payload strategies
- Specifically and based on the platform versatility, systematically exploring degrader-based payloads to broaden the scope of intracellular payload targets
5:00 pm Contextualizing the Clinical Journey of Belantamab Mafodotin as a BCMA Targeting ADC in Treatment of Relapsed or Refractory Multiple Myeloma
Synopsis
- Exploring preclinical evidence of Belantamab Mafodotin’s underlying mechanism of action in support of monotherapy development and rationale for synergy in combination
- Breaking down the clinical journey from statistically negative DREAMM-3 monotherapy readout to positive combination therapy data with DREAMM-7 and DREAMM-8
- Explaining the regulatory vs. clinical journey to better understand strength of evidence of Belantamab Mafodotin as a monotherapy and in combinations.
5:30 pm Chair’s Closing Remarks
6:00 pm
11th World ADC Awards
In Partnership with AMBRX | Johnson & Johnson
Synopsis
Celebrating 11 Years of Recognizing the Top Calibre, Achievement & Influence in ADC Development
At the end of the main conference days, join us for an unforgettable evening honoring the best companies, teams, programs, and individuals in the ADC field.
Across 10 categories, this is your opportunity to recognize the amazing individual, project, and company-wide creativity, innovation, leadership, and devotion made by your peers over the past 12 months. Make sure you have your say and nominate your favorite contributors that have propelled ADCs to be biopharma’s hottest therapeutic modality at the forefront oncology R&D and dealmaking, and those working towards making ADCs standard of care treatments in oncology and beyond.
Visit our website for more information: 5:30 11th World ADC Awards www.worldadc-awards.com
8:00 pm End of Scientific Program Day Two
